Itsuwa 2023: Decline in Revenue and Profit, Controllers Voluntarily Waiving $690,000 Bonuses

Business by 2FIRSTS, edited by Sophia
Apr.28.2024
Itsuwa 2023: Decline in Revenue and Profit, Controllers Voluntarily Waiving $690,000 Bonuses
Itsuwa's 2023 annual report reveals a significant decline in revenue and profit due to domestic and overseas market challenges.

On April 26th, Itsuwa released its 2023 annual report. During 2023, the company's operating income was 327 million yuan, a decrease of 49.85% compared to the previous year. Net profit attributable to the listed company's shareholders was 22.1272 million yuan, a decrease of 72.75% year-on-year.

 

Itsuwa 2023: Decline in Revenue and Profit, Controllers Voluntarily Waiving $690,000 Bonuses
2023 Annual Report | Image source: Itsuwa

 

The Itsuwa report shows that the company primarily employs an "ODM/OEM production and designated sales" business and sales model, supplying e-cigarettes and their related products to overseas e-cigarette brands for revenue, profit, and cash flow.

 

According to the Itsuwa report, the main reasons for the decline in income are: the impact of e-cigarette policies, the domestic ban on the sale of flavored e-cigarettes other than tobacco flavor, leading to increased competition in overseas markets.

 

The company's main operating gross profit margins in 2021, 2022, and 2023 were 26.20%, 28.56%, and 36.08% respectively. The gross profit margin in 2023 increased, primarily due to the appreciation of the US dollar exchange rate, an increase in the selling price converted to Renminbi compared to the same period last year, and a decrease in prices of key upstream raw materials such as batteries and microphones.

 

It is worth noting that the report highlights that their research and development products include disposable e-cigarettes, pod-system e-cigarettes, with a focus on environmental protection, modularity, and multiple pods.

 

  • The company has developed a biodegradable disposable e-cigarette product in compliance with environmental regulations. The product features a biodegradable shell and a modular design, allowing consumers to return it to designated dealers after use. Dealers can then disassemble the product into biodegradable shells and rechargeable batteries, which can be processed back into disposable e-cigarette products. This product is easy to assemble, has a biodegradable shell, and allows for the reuse of batteries, making it environmentally friendly.
  •  
  • In order to improve the user experience, the company has developed a line of multi-pod products. These pods can be easily interchanged with different flavors and feature a unique rotating structure for convenient and quick switching.

 

Since 2017, the company has actively promoted its own brands of e-cigarettes, such as VAPESOUL and VOOM, targeting different consumer groups with each brand. The sales of own-brand products account for 23.39% of total sales in this period. In 2024, the company plans to continue promoting the sales of its own brand e-cigarettes.

 

Itsuwa mentioned that the two actual controllers of the company, due to the difficulties in business operations in 2023 compared to the previous year (sub-company Shenzhen Wudian Technology Co., Ltd. did not obtain a tobacco monopoly license, resulting in the cessation of e-cigarette business operations, reducing the overall e-cigarette production capacity of the company, and the short-term benefits of its business transformation could not be achieved), have voluntarily waived their personal bonuses for the 2022 fiscal year amounting to 4,999,110.00 yuan in order to alleviate the company's financial pressure.

 

Itsuwa stated that, based on the industry's current situation, regulations are becoming stricter, competition is intensifying, and companies are facing increasing challenges.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Imperial Brands' acquisition of Swedish Helwit owner Yoik Group AB has highlighted the professional-services firms supporting cross-border oral nicotine M&A. Latham & Watkins and KPMG advised Imperial, while PwC and TM & Partners advised Yoik. KPMG also appeared on Imperial's acquisition of Black Buffalo earlier in 2026, while PwC played an extensive role in KT&G's acquisition of Swedish nicotine-pouch company Another Snus Factory. Imperial's public disclosures put the global modern oral nicotine delivery market at approximately £8.8 billion in retail sales and 23.5 billion pouches in 2024
Sep.20
Ispire Q4 Revenue Rebounds 33% but Full-Year Sales Still Fall 25% as FY2027 Focus Shifts to Malaysia Manufacturing, ODM, Nicotine Pouches and Age Verification
Ispire Q4 Revenue Rebounds 33% but Full-Year Sales Still Fall 25% as FY2027 Focus Shifts to Malaysia Manufacturing, ODM, Nicotine Pouches and Age Verification
Ispire Technology reported FY2026 revenue of about $96 million, down 24.7% year over year, as U.S. cannabis-vapor hardware and European e-cigarette sales declined by $17.4 million and $12.7 million, respectively. Fourth-quarter revenue rose 32.5% to $26.7 million, while quarterly gross margin fell to 6.3%. For FY2027, the company is prioritizing Malaysia manufacturing and vapor ODM while continuing to develop nicotine pouches, IKE Tech age-verification technology and G-Mesh licensing. Ispire has not separately disclosed the revenue or profit contribution of those newer businesses.
Regulations
Sep.17 by 2Firsts Perspectives
EU Commission Clarifies Vaping, Smokeless Nicotine Use in Proposed Cardiovascular Checks
EU Commission Clarifies Vaping, Smokeless Nicotine Use in Proposed Cardiovascular Checks
The European Commission has clarified to 2Firsts that its proposed cardiovascular health checks would assess smoking, vaping and the use of smokeless nicotine products as part of patients’ medical histories. The Commission also said Member States may organise additional checks within their healthcare systems. In the same response, it pointed to JRC research on e-cigarettes, heated tobacco products and nicotine pouches that has fed into the evaluation of EU tobacco legislation.
Nov.09
Vape Manufacturer Ispire Expands Malaysia Operations, Negotiates Southeast Asia OEM Deal as Nicotine Pouch and US Age-Gating Businesses Develop
Vape Manufacturer Ispire Expands Malaysia Operations, Negotiates Southeast Asia OEM Deal as Nicotine Pouch and US Age-Gating Businesses Develop
US-listed vaping technology and manufacturing company Ispire Technology reported fiscal first-quarter 2027 revenue of $27.5 million on November 9, 2026, down 9.3% year over year but up 3.2% sequentially. Gross margin recovered to 16.2%, while its net loss widened to $6.4 million from $3.3 million a year earlier. Management attributed the sales decline primarily to tighter European vaping regulation and reduced distributor orders. Ispire is expanding manufacturing in Malaysia and negotiating an OEM/ODM agreement with a Southeast Asian vaping brand, with an announcement anticipated in January 2027. The company estimates that Malaysian manufacturing offers an approximately 25% US tariff advantage over China-based production. However, it continues to purchase products from Shenzhen Yi Jia Technology Co., Ltd., a manufacturer controlled by its chairman, and reported $52 million in non-current related-party payables at September 30.
company
Nov.11 by 2Firsts Perspectives
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
American Vapor Manufacturers (AVM) and Altria subsidiaries Helix Innovations and NJOY filed separate motions on October 7, 2026, seeking to intervene on the FDA's side in a lawsuit challenging its enforcement guidance for certain e-cigarette and nicotine pouch products with pending premarket tobacco product applications (PMTAs). Seven public health and tobacco-control organizations, including the Campaign for Tobacco-Free Kids, sued the agency in July to overturn the policy. AVM argues that vacating the guidance could disrupt orders, inventory, retail distribution and investments in regulatory submissions.
Regulations
Oct.09
On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
FDA CTP Director Bret Koplow used his FDLI keynote in Washington to outline how the agency is rethinking the PMTA framework. He discussed category-specific review, nicotine pouch and sPMTA pilots, AI-assisted review, a 70% reduction in pending applications, and a major staffing constraint: CTP currently has only nine scientific review teams. He also reaffirmed tobacco harm reduction while stressing youth protection, flavored products, risk communication, and the challenge of unauthorized e-cigarettes.
Regulations
Oct.06